| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20011676 | HPV | ENSG00000152578.15 | protein_coding | GRIA4 | No | No | 2893 | P48058 Q1WWK6 |
| TVIS20049996 | HPV | ENSG00000152578.15 | protein_coding | GRIA4 | No | No | 2893 | P48058 Q1WWK6 |
| TVIS20027241 | HPV | ENSG00000152578.15 | protein_coding | GRIA4 | No | No | 2893 | P48058 Q1WWK6 |
| TVIS44030164 | HTLV-1 | ENSG00000152578.15 | protein_coding | GRIA4 | No | No | 2893 | P48058 Q1WWK6 |
| TVIS44049369 | HTLV-1 | ENSG00000152578.15 | protein_coding | GRIA4 | No | No | 2893 | P48058 Q1WWK6 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GRIA4 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000830 |
| UniProt ID | P48058 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 11406192; 7679210; 12008069 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Linden AM, Yu H, Zarrinmayeh H, Wheeler WJ, Skolnick P: Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology. 2001 Jun;40(8):1010-8.@@Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.@@Cristovao AJ, Oliveira CR, Carvalho CM: Expression of AMPA/kainate receptors during development of chick embryo retina cells: in vitro versus in vivo studies. Int J Dev Neurosci. 2002 Feb;20(1):1-9. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
